Erratum: Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer(Nature (2014) 510 (407-411) 10.1038/nature13444);Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer

Nature

Volumn 510, Issue 7505, 2014, Pages 407-411

  Ali, Khaled ^a,g   Soond, Dalya R ^b,h   Piñeiro, Roberto ^a   Hagemann, Thorsten ^c   Pearce, Wayne ^a   Lim, Ee Lyn ^b   Bouabe, Hicham ^b   Scudamore, Cheryl L ^d   Hancox, Timothy ^e   Maecker, Heather ^f   Friedman, Lori ^f   Turner, Martin ^b   Okkenhaug, Klaus ^b   Vanhaesebroeck, Bart ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b BABRAHAM INSTITUTE   (United Kingdom)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d Medical Research Council Harwell Institute   (United Kingdom)

^e Piramed Pharma   (United Kingdom)

^f GENENTECH INC   (United States)

^g AMGEN INC   (United States)

^h UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD38 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HERMES ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 6; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN P110; PROTEIN P110 DELTA; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULOTROPIN;

BLOOD SYSTEM DISORDER; CANCER; DISEASE RESISTANCE; DISEASE TREATMENT; DRUG; IMMUNITY; INHIBITOR; PUBLIC HEALTH; TOLERANCE; TUMOR;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ENZYME INACTIVATION; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE ACTIVATION; MACROPHAGE; MOUSE; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SPLEEN CELL; SUPPRESSOR CELL; T LYMPHOCYTE; TUMOR RESISTANCE; WILD TYPE;

MUS;

ANIMALS; ANTINEOPLASTIC AGENTS; ENZYME ACTIVATION; ENZYME INHIBITORS; IMMUNE TOLERANCE; MICE; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; T-LYMPHOCYTES, REGULATORY;

EID: 84903188335     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature17641     Document Type: Erratum

References (23)

1. Furman, R. R. et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 370, 997-1007 (2014).
2. Gopal, A. K. et al. PI3Kd inhibition by idelalisib in patients with relapsed indolent lymphoma. N. Engl. J. Med. 370, 1008-1018 (2014).
3. Vanhaesebroeck, B. et al. P110d, a novel phosphoinositide 3-kinase in leukocytes. Proc. Natl Acad. Sci. USA 94, 4330-4335 (1997).
4. Fruman, D. A. & Rommel, C. PI3K and cancer: lessons, challenges and opportunities. Nature Rev. Drug Discov. 13, 140-156 (2014).
5. Okkenhaug, K. et al. Impaired B and T cell antigen receptor signaling in p110D PI 3-kinase mutant mice. Science 297, 1031-1034 (2002).
6. Okkenhaug, K. Signaling by the phosphoinositide 3-kinase family in immune cells. Annu. Rev. Immunol. 31, 675-704 (2013).
7. Curiel, T. J. Regulatory T cells and treatment of cancer. Curr. Opin. Immunol. 20, 241-246 (2008).
8. Patton, D. T. et al. Cutting edge: the phosphoinositide 3-kinase p110d is critical for the function of CD41CD251Foxp31 regulatory T cells. J. Immunol. 177, 6598-6602 (2006).
9. Patton,D.T.,Wilson,M.D.,Rowan,W.C., Soond,D.R.&Okkenhaug,K. ThePI3Kp110d regulates expression of CD38 on regulatory T cells. PLoS ONE 6, e17359 (2011).
10. Muranski, P. & Restifo, N. P. Adoptive immunotherapy of cancer using CD41 T cells. Curr. Opin. Immunol. 21, 200-208 (2009).
11. Soond, D. R. et al. Pten loss in CD4 T cells enhances their helper function but does not lead to autoimmunity or lymphoma. J. Immunol. 188, 5935-5943 (2012).
12. Okkenhaug, K. et al. The p110d isoform of phosphoinositide 3-kinase controls clonal expansion and differentiation of Th cells. J. Immunol. 177, 5122-5128 (2006).
13. Soond, D. R. et al. PI3K p110d regulates T-cell cytokine production during primary and secondary immune responses in mice and humans. Blood 115, 2203-2213 (2010).
14. Pulaski, B. A.,Smyth, M. J.& Ostrand-Rosenberg, S. Interferon-gamma-dependent phagocytic cells are a critical component of innate immunity against metastatic mammary carcinoma. Cancer Res. 62, 4406-4412 (2002).
15. Gabrilovich, D. I., Ostrand-Rosenberg, S. & Bronte, V. Coordinated regulation of myeloid cells by tumours. Nature Rev. Immunol. 12, 253-268 (2012).
16. Bunt, S. K., Sinha, P., Clements, V. K., Leips, J. & Ostrand-Rosenberg, S. Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J. Immunol. 176, 284-290 (2006).
17. Youn, J. I., Nagaraj, S., Collazo, M. & Gabrilovich, D. I. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J. Immunol. 181, 5791-5802 (2008).
18. Putz, E. M. et al. PI3Kd is essential for tumor clearance mediated by cytotoxic T lymphocytes. PLoS ONE 7, e40852 (2012).
19. Gattinoni, L., Klebanoff, C. A. & Restifo, N. P. Paths to stemness: building the ultimate antitumour T cell. Nature Rev. Cancer 12, 671-684 (2012).
20. Schmid, M. C. et al. Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3Kc, a single convergent point promoting tumor inflammation and progression. Cancer Cell 19, 715-727 (2011).
21. Soler, A. et al. Inhibition of the p110a isoform of PI 3-kinase stimulates nonfunctional tumor angiogenesis. J. Exp. Med. 210, 1937-1945 (2013).
22. Murray, J. M. et al. Potent and highly selective benzimidazole inhibitors of PI3-kinase delta. J. Med. Chem. 55, 7686-7695 (2012).
23. Safina, B. S. et al. Discovery of novel PI3-kinase d specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition. J. Med. Chem. 55, 5887-5900 (2012).